CAMBRIDGE, Mass., April 22, 2015—Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 technology for gene editing and repair, announced today the appointment of Dr. Sapna Srivastava as Chief Financial and Strategy Officer.
“Our management team is being further enhanced by the addition of Dr. Sapna Srivastava,” said Nessan Bermingham, PhD, Chief Executive Officer of Intellia. “As a leading Wall Street biotechnology analyst for over a decade, as well as a business and strategy advisor to biopharmaceutical companies, Sapna’s extensive experience and understanding of the industry and capital markets will contribute to the implementation and advancement of our product development, partnering and financing strategies.”
Dr. Srivastava has more than a decade of experience in the biopharmaceutical industry and Wall Street. She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners, LLC, and began her career as a research associate at JP Morgan. Since 2012, Dr. Srivastava has served as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology companies, and co-founded a neuroscience focused biotechnology company. Dr. Srivastava received her PhD in neuroscience from New York University.
“Intellia is a remarkable combination of world-class science and people. I am delighted to join the Intellia team, taking a direct role in helping to build this revolutionary CRISPR/Cas9 technology, which has the potential to change the course of medicine,” said Dr. Srivastava. “I’m excited to be part of the Intellia team, which is focused on realizing the potential of this technology to develop drugs for patients with significant unmet medical needs. I am looking forward to helping to contribute and accelerate the company’s growth in this new position.”
About Intellia Therapeutics
Intellia Therapeutics was formed in 2014 to develop curative medicines, utilizing the promise of the CRISPR/Cas9 technology. Intellia holds exclusive access to one of the broadest intellectual property platforms available for the therapeutic use of CRISPR/Cas9. Intellia is backed by Atlas Venture and Novartis Institutes for Biomedical Research. In January of this year, Intellia Therapeutics announced a large partnering deal with Novartis for CAR-T and HSC applications of the technology. For more information, please visit intelliatx.com.